|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Eltabbakh GH and Awtrey CS: Current
treatment for ovarian cancer. Expert Opin Pharmacother. 2:109–124.
2001. View Article : Google Scholar
|
|
3
|
Herzog TJ: The current treatment of
recurrent ovarian cancer. Curr Oncol Rep. 8:448–454. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wakil SJ, Stoops JK and Joshi VC: Fatty
acid synthesis and its regulation. Annu Rev Biochem. 52:537–579.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barber MC, Price NT and Travers MT:
Structure and regulation of acetyl-CoA carboxylase genes of
metazoa. Biochim Biophys Acta. 1733:1–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Griffin MJ and Sul HS: Insulin regulation
of fatty acid synthase gene transcription: roles of USF and
SREBP-1c. IUBMB Life. 56:595–600. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hardie DG and Pan DA: Regulation of fatty
acid synthesis and oxidation by the AMP-activated protein kinase.
Biochem Soc Trans. 30(Pt 6): 1064–1070. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abu-Elheiga L, Brinkley WR, Zhong L,
Chirala SS, Woldegiorgis G and Wakil SJ: The subcellular
localization of acetyl-CoA carboxylase. Proc Natl Acad Sci USA.
97:1444–1449. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen ZP, McConell GK, Michell BJ, Snow RJ,
Canny BJ and Kemp BE: AMPK signaling in contracting human skeletal
muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am
J Physiol Endocrinol Metab. 279:E1202–E1206. 2000.PubMed/NCBI
|
|
10
|
Milgraum LZ, Witters LA, Pasternack GR and
Kuhajda FP: Enzymes of the fatty acid synthesis pathway are highly
expressed in in situ breast carcinoma. Clin Cancer Res.
3:2115–2120. 1997.PubMed/NCBI
|
|
11
|
Witters LA, Widmer J, King AN, Fassihi K
and Kuhajda F: Identification of human acetyl-CoA carboxylase
isozymes in tissue and in breast cancer cells. Int J Biochem.
26:589–594. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yahagi N, Shimano H, Hasegawa K, Ohashi K,
Matsuzaka T, Najima Y, Sekiya M, Tomita S, Okazaki H, Tamura Y,
Iizuka Y, Ohashi K, Nagai R, Ishibashi S, Kadowaki T, Makuuchi M,
Ohnishi S, Osuga J and Yamada N: Co-ordinate activation of
lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer.
41:1316–1322. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chajès V, Cambot M, Moreau K, Lenoir GM
and Joulin V: Acetyl-CoA carboxylase alpha is essential to breast
cancer cell survival. Cancer Res. 66:5287–5294. 2006.PubMed/NCBI
|
|
14
|
Brusselmans K, De Schrijver E, Verhoeven G
and Swinnen JV: RNA interference-mediated silencing of the
acetyl-CoA-carboxylase-alpha gene induces growth inhibition and
apoptosis of prostate cancer cells. Cancer Res. 65:6719–6725. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang C, Xu C, Sun M, Luo D, Liao DF and
Cao D: Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human
cancer cell apoptosis. Biochem Biophys Res Commun. 385:302–306.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McCune SA and Harris RA: Mechanism
responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of
hepatic lipogenesis. J Biol Chem. 254:10095–10101. 1979.PubMed/NCBI
|
|
17
|
Tong L and Harwood HJ Jr: Acetyl-coenzyme
A carboxylases: versatile targets for drug discovery. J Cell
Biochem. 99:1476–1488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harwood HJ Jr: Treating the metabolic
syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther
Targets. 9:267–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Halvorson DL and McCune SA: Inhibition of
fatty acid synthesis in isolated adipocytes by
5-(tetradecyloxy)-2-furoic acid. Lipids. 19:851–856. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guseva NV, Rokhlin OW, Glover RA and Cohen
MB: TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid
synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and
kills prostate cancer cells independent of p53 status. Cancer Biol
Ther. 12:80–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oda T, Hayano T, Miyaso H, Takahashi N and
Yamashita T: Hsp90 regulates the Fanconi anemia DNA damage response
pathway. Blood. 109:5016–5026. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhong Q, Wen YJ, Yang HS, Luo H, Fu AF,
Yang F, Chen LJ, Chen X, Qi XR, Lin HG, Wan Y, Chen XC, Wei YQ and
Zhao X: Efficient inhibition of cisplatin-resistant human ovarian
cancer growth and prolonged survival by gene transferred vesicular
stomatitis virus matrix protein in nude mice. Ann Oncol.
19:1584–1591. 2008. View Article : Google Scholar
|
|
23
|
Kuhajda FP: Fatty-acid synthase and human
cancer: new perspectives on its role in tumor biology. Nutrition.
16:202–208. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou W, Han WF, Landree LE, Thupari JN,
Pinn ML, Bililign T, Kim EK, Vadlamudi A, Medghalchi SM, El Meskini
R, Ronnett GV, Townsend CA and Kuhajda FP: Fatty acid synthase
inhibition activates AMP-activated protein kinase in SKOV3 human
ovarian cancer cells. Cancer Res. 67:2964–2971. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
D’Andrilli G, Kumar C, Scambia G and
Giordano A: Cell cycle genes in ovarian cancer: steps toward
earlier diagnosis and novel therapies. Clin Cancer Res.
10:8132–8141. 2004.PubMed/NCBI
|
|
26
|
Aggarwal P, Vaites LP, Kim JK, Mellert H,
Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB and
Diehl JA: Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression
and triggers neoplastic growth via activation of the PRMT5
methyltransferase. Cancer Cell. 18:329–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ray H, Suau F, Vincent A and Dalla Venezia
N: Cell cycle regulation of the BRCA1/acetyl-CoA-carboxylase
complex. Biochem Biophys Res Commun. 378:615–619. 2009. View Article : Google Scholar : PubMed/NCBI
|
